The Organoid biobanks created by HUB and partners consists of more than 800 organoid cultures representing a variety of organs and disease models. As monogenetic diseases, HUB organoid biobank includes intestinal and lung organoids from cystic fibrosis patients and liver organoids from patients with metabolic diseases (alpha-1 antitrypsin, Crigler-Najjar, etc.). The HUB organoid biobank also has an important representation of cancer models including colorectal, intestinal pancreatic, lung and breast tumour organoids. For some of these cancer models, organoids derived from normal (cancer-free) adjacent tissue are available.
Using the Living Biobank, the HUB explores novel therapeutic strategies, including responsiveness to drug combinations, to develop rules for patient stratification based on drug sensitivity in vitro. Connecting genomic heterogeneity and gene function to in vitro drug responsiveness will lead to the development of a road map for improved treatment strategies.